Email : info@nexusalliancebiopharma.com
Contact : (321) 445-1969

New Targets in Treating Multiple Myeloma

Abstract

Multiple myeloma is one of the chronic lymph proliferative disorders that mainly affect elderly population. Despite the fact that various lines of treatment have been suggested and approved for this type of hematologic malignancy and autologous stem cell transplantation has also been applied for eligible patients, the optimal combination and sequence of therapy is yet to be determined in majority of patients. One of the main reasons for this treatment dilemma is the incurable nature of the disease. Moreover, the malignant cells, show distinct clonal features with a variable response to these suggested therapeutic approach and further genetic changes may happen once the disease has been progressed hence, the treatment may be extremely difficult in the relapsed cases. This review mainly focuses on the available immunotherapy in multiple myeloma and ongoing clinical trials for immunotherapy in multiple myeloma.

Download Pdf